Compare Ishares Msci Italy ETF (EWI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Revvity Inc — how do they compare? Ishares Msci Italy ETF trades at $56.32 (market cap $1.14B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 14.9× Ishares Msci Italy ETF's market cap, and Revvity Inc pays a 0.18% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 53 Days and Revvity Inc for 12 Days on average.
| EWI | RVTY | |
|---|---|---|
Market Cap | $1.14B | $16.98B |
Volume | 2,377,947 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $157.36 |
52-Week Low | $50.31 | $82.26 |
Typical Hold Time | 53 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI (iShares MSCI Italy ETF) trades at $56.32, down slightly by 0.05% with a bearish technical signal from moving averages and oscillators. The ETF provides concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU recovery investments. Recent news highlights European Central Bank rate hikes and energy price pressures affecting eurozone markets.
The outlook remains cautious due to technical bearish signals and macroeconomic headwinds from ECB tightening. Investment opportunity lies in Italy's banking consolidation and infrastructure spending, but risks include eurozone economic sentiment deterioration and persistent inflation concerns.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
